Takeda Outlicenses Two CCR5 Antagonists To Newly Formed Tobira
This article was originally published in PharmAsia News
Executive Summary
A new chemokine receptor 5 antagonist candidate licensed this week to Tobira Therapeutics by Takeda could provide a dosing advantage over other CCR5 antagonists in development, such as Pfizer's maraviroc and Schering-Plough's vicriviroc, according to Tobira CEO James Sapirstein